Search
for
Sort by
Research 91–120 of 180
- Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
- The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Persistent hair growth during treatment with the EGFR inhibitor erlotinib
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin
- Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
- The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series
- Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment
- Epidermal growth factor receptor inhibitors and hair
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Alopecia and drug eruption of the scalp associated with a new beta-blocker, nadolol.
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Review of Drug Repositioning in Cancer Therapeutics
- Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
- Clinical Value Analysis of Pemetrexed Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Activation of Nrf2 in keratinocytes causes chloracne (MADISH)‐like skin disease in mice
- Corticosterone inhibits GAS6 to govern hair follicle stem-cell quiescence
- Wedelolactone Attenuates Pulmonary Fibrosis Partly Through Activating AMPK and Regulating Raf-MAPKs Signaling Pathway
- Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer
- Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth?